Background: Chloroquine or hydroxychloroquine (chloroquine) plus azithromycin is considered as therapy for COVID-19. With benefit evaluations underway, safety concerns due to potential additive effects on QTc prolongation should be addressed.
Objective: We compared risk of cardiac adverse events between combinations of chloroquine and azithromycin and chloroquine and amoxicillin.
Methods: We conducted a retrospective cohort study using the IBM MarketScan Commercial Claims and Medicare Supplemental Databases, 2005-2018. We included autoimmune disease patients aged ≥18 years initiating azithromycin or amoxicillin for ≥5 days during chloroquine treatment. Patients had continuous insurance coverage ≥6 months before combination use until 5 days thereafter or inpatient death. Two outcomes were sudden cardiac arrest/ventricular arrhythmias (SCA/VA) and cardiac symptoms. We followed patients for up to 5 days to estimate hazard ratios (HR). Covariates were adjusted using stabilized inverse probability treatment weighting.
Results: We identified two SVC/VA events among >145,000 combination users. The adjusted incidence of cardiac symptoms among azithromycin and amoxicillin users was 276 vs 254 per 10,000 person-years with an adjusted HR of 1.10 (95%CI, 0.62-1.95).
Conclusion: Combination use of chloroquine and azithromycin at routine doses did not show pronounced increases in arrhythmias in this real-world population, though small sample size and outcome rates limit conclusions.
Keywords: COVID19; Cardiac events; Chloroquine; Hydroxychloroquine; QTc prolongation.
Copyright © 2020 Elsevier Inc. All rights reserved.
The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection.Circ Arrhythm Electrophysiol. 2020 Apr 29. doi: 10.1161/CIRCEP.120.008662. Online ahead of print. Circ Arrhythm Electrophysiol. 2020. PMID: 32347743
Concomitant Use of Quinolones and Stimulants and the Risk of Adverse Cardiovascular Symptoms: A Retrospective Cohort Study.Pharmacotherapy. 2019 Dec;39(12):1167-1178. doi: 10.1002/phar.2343. Epub 2019 Nov 25. Pharmacotherapy. 2019. PMID: 31674031
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.Res Social Adm Pharm. 2020 Apr 19:S1551-7411(20)30391-0. doi: 10.1016/j.sapharm.2020.04.016. Online ahead of print. Res Social Adm Pharm. 2020. PMID: 32327397 Free PMC article.
Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19.Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4539-4547. doi: 10.26355/eurrev_202004_21038. Eur Rev Med Pharmacol Sci. 2020. PMID: 32373993 Review.
Azithromycin for treating uncomplicated malaria.Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD006688. doi: 10.1002/14651858.CD006688.pub2. Cochrane Database Syst Rev. 2011. PMID: 21328286 Free PMC article. Review.
- Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. February. 2020 doi: 10.1001/jama.2020.2648. - DOI
- World Health Organization Coronavirus Disease 2019 (COVID-19) Situation Report - 95. April 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
- Gautret P., Lagier J.-C., Parola P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. March. 2020:105949. doi: 10.1016/j.ijantimicag.2020.105949. - DOI
- Molina J., Delaugerre C., Goff J. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. March. 2020 doi: 10.1016/j.medmal.2020.03.006. - DOI
- Shah S., Das S., Jain A., Misra D.P., Negi V.S. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19) Int J Rheum Dis. April 2020 doi: 10.1111/1756-185X.13842. - DOI